Search Results - "Liberato, L N"

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia by BAROSI, G, MARCHETTI, M, LIBERATO, N. L

“…Recombinant human erythropoietin (rHuEPO) has been advocated for the treatment of anaemia in patients submitted to cancer chemotherapy. We used decision…”
Get full text

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia by Barosi, Giovanni, Ambrosetti, Achille, Finelli, Carlo, Grossi, Alberto, Leoni, Pietro, Liberato, Nicola L., Petti, Maria C., Pogliani, Enrico, Ricetti, Marilena, Rupoli, Serena, Visani, Giuseppe, Tura, Sante

“…The purpose of this work was to develop a definition of myelofibrosis with myeloid metaplasia (MMM) using diagnostic criteria that would remain valid within…”
Get full text

Cost-effectiveness of interferon alfa in chronic myelogenous leukemia by Liberato, N L, Quaglini, S, Barosi, G

“…To evaluate the cost-effectiveness of interferon alfa (IFN alpha) treatment of patients with chronic myelogenous leukemia relative to conventional…”
Get more information

Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost–utility analysis by Liberato, N.L., Rognoni, C., Rubrichi, S., Quaglini, S., Marchetti, M., Gorlia, T., Licitra, L., Vermorken, J.B.

“…Adding docetaxel (Taxotere, T) to induction chemotherapy with platinum/infusional 5-FU (PF) has been shown to improve overall survival of patients with head…”
Get full text

Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction by Barosi, G, Ambrosetti, A, Buratti, A, Finelli, C, Liberato, N L, Quaglini, S, Ricetti, M M, Visani, G, Tura, S, Ascari, E

“…Since according to the early studies, the outcome after splenectomy in the individual patient with myelofibrosis with myeloid metaplasia (MMM) is…”
Get more information

Subcutaneous Erythropoietin for Treatment of Refractory Anemia in Hematologic Disorders. Results of a Phase I/II Clinical Trial by Cazzola, Mario, Ponchio, Luisa, Beguin, Yves, Rosti, Vittorio, Bergamaschi, Gaetano, Liberato, Nicola L., Fregoni, Vittorio, Nalli, Giulio, Barosi, Giovanni, Ascari, Edoardo

“…We have used recombinant human erythropoietin (rHuEPO) in a phase I/II clinical trial to evaluate its ability to reverse refractory anemia in hematologic…”
Get full text

A prognostic classification of myelofibrosis with myeloid metaplasia by Barosi, G, Berzuini, C, Liberato, L N, Costa, A, Polino, G, Ascari, E

“…The dependence of survival time on a set of prognostic factors was explored by means of Cox's regression model in 137 cases of myelofibrosis with myeloid…”
Get more information

Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia by Barosi, G, Liberato, L N, Guarnone, R

“…Serum erythropoietin levels (s-Epo) were measured by radioimmunoassay in 61 consecutive anaemic patients (Hb < 12 g/dl) with myelofibrosis with myeloid…”
Get more information

Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin β-thalassemia intermedia patients by GALANELLO, R, BARELLA, S, TURCO, M. P, GIAGU, N, CAO, A, DORE, F, LIBERATO, N. L, GUARNONE, R, BAROSI, G

“…Clinical data suggest that in beta-thalassemia-intermedia patients, higher levels of circulating fetal hemoglobin (HbF) are associated with greater disease…”
Get full text

Warfarin resistance induced by teicoplanin by Agosta, F G, Liberato, N L, Chiofalo, F

Get full text

Autoimmune hemolytic anemia in multicentric Castleman's disease by Liberato, NL, Bollati, P, Chiofalo, F, Filipponi, M, Poli, M

“…Divisione di Medicina, Ospedale C. Mira, Casorate Primo, Italy. We report on a patient affected by multicentric Castleman's disease who developed an acute…”
Get full text

Beyond bayes by MARCHETTI, M, LIBERATO, N. L, BAROSI, G

Get full text

An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression by Barosi, G, Buratti, A, Costa, A, Liberato, L N, Balduini, C, Cazzola, M, Rosti, V, Magrini, U, Ascari, E

“…Among 761 consecutive patients with chronic myeloproliferative disorders (CMD), it was found that 18 (nine men and nine women) did not fulfill at presentation…”
Get more information

Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia by Barosi, G, Liberato, L N, Costa, A, Ascari, E

“…In an attempt to reduce myeloproliferation, we administered recombinant alpha-2b interferon (r-alpha INF) to ten patients with myelofibrosis with myeloid…”
Get full text

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) by Barosi, Giovanni, Bordessoule, Dominique, Briere, Jean, Cervantes, Francisco, Demory, Jean-Loup, Dupriez, Brigitte, Gisslinger, Heinz, Griesshammer, Martin, Hasselbalch, Hans, Kusec, Rajko, Le Bousse-Kerdiles, Marie-Caroline, Liberato, Nicola L., Marchetti, Monia, Reilly, John T., Thiele, Jurgen

“…The European Myelofibrosis Network (EUMNET), a European research network on myelofibrosis with myeloid metaplasia (MMM), has developed a definition of response…”
Get full text

Erythropoietin: biological aspects and clinical usefulness by Liberato, N L, Costa, A, Barosi, G

“…In the eighties there has been an enormous increase in our knowledge about erythropoietin, previously defined as "an elusive hormone". In this review we…”
Get more information

Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease by Barosi, G, Merlo, C, Palestra, P, Liberato, N L, Guarnone, R, Di Dio, F, Piazza, V, Salvadeo, A

“…In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal…”
Get more information

Bromocriptine-induced acute hepatitis by Liberato, N L, Poli, M, Bollati, P, Chiofalo, F, Filipponi, M

Get more information

Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia by Barosi, G, Costa, A, Liberato, L N, Polino, G, Spriano, P, Magrini, U

“…In 78 patients with myelofibrosis with myeloid metaplasia (MMM) the serum procollagen III peptide activity (s-PIIIP) had a higher mean value than in 22 normal…”
Get more information

Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia by Barosi, G, Liberato, L N, Costa, A, Buratti, A, Di Dio, F, Salvatore, S, Ascari, E

“…In 12 patients having myelofibrosis with myeloid metaplasia (MMM), recombinant- alpha interferon (r-alpha INF) was given for 16 weeks at an initial dose of 3 x…”
Get more information